-
Roche says Herceptin with Pertuzumab “impressive”
Jun 01, 08 Drug NewsRoche Holding AG’s Herceptin combined with pertuzumab showed “impressive results” in a phase II breast cancer trial, the Swiss drugmaker said on Friday.
The company also cited a late-stage trial showing that Herceptin treatment prevented disease progression in women with aggressive metastatic breast cancer.
In the trial, women with breast cancer received either Herceptin—which is also known as trastuzumab—with Xeloda, another Roche drug, or Xeloda alone.
The data are due to be presented at an American Society of Clinical Oncology (ASCO) meeting.
ZURICH (Reuters)
Also in this section:
Subscribe to the "News" RSS Feed 
TOP ۞
